Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

We recently published a clinically-meaningful improvement in median overall survival (OS) for patients with acute myeloid leukaemia (AML), >30% bone marrow (BM) blasts and white blood cell (WBC) count ≤15 G/L, treated with front-line azacitidine versus conventional care regimens within a phase 3...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Mol Sci
Главные авторы: Pleyer, Lisa, Döhner, Hartmut, Dombret, Hervé, Seymour, John F., Schuh, Andre C., Beach, CL, Swern, Arlene S., Burgstaller, Sonja, Stauder, Reinhard, Girschikofsky, Michael, Sill, Heinz, Schlick, Konstantin, Thaler, Josef, Halter, Britta, Machherndl Spandl, Sigrid, Zebisch, Armin, Pichler, Angelika, Pfeilstöcker, Michael, Autzinger, Eva M., Lang, Alois, Geissler, Klaus, Voskova, Daniela, Sperr, Wolfgang R., Hojas, Sabine, Rogulj, Inga M., Andel, Johannes, Greil, Richard
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5343949/
https://ncbi.nlm.nih.gov/pubmed/28212292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18020415
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы